Pharmexa Provides Update on HeptoVax Trial
UK drugmaker Pharmexa has provided an update of its Phase II HeptoVax trial, in which patients with advanced hepatocellular carcinoma received GV1001.
The company has completed enrollment in Spain, France and Germany, and 14 patients are still on treatment with GV1001. In the first 21 patients, all six doses were well tolerated and no vaccine-attributable serious adverse effects were observed, Pharmexa said.
Final trial results will include an analysis of safety, immunogenicity, tumor response, time-to-progression and survival and will be available before the end of the second quarter of 2008.